Abstracts tagged "human leukocyte antigens (HLA) and vasculitis"

Abstract Number: 892 • 2013 ACR/ARHP Annual Meeting
The Functional PTPN22 Variant R620W Is Strongly Associated With Giant Cell Artetitis Predisposition
F. David Carmona¹, Sarah L. Mackie², Aurora Serrano³, Ana Marquez⁴, Roser Solans⁵, Jose A. Miranda-Filloy⁶, Jose Hernández-Rodríguez⁷, Maria C. Cid⁸, Santos Castañeda⁹, Inmaculada C. Morado¹⁰, Javier Narvaez¹¹, Ricardo Blanco¹², Bernardo Sopeña¹³, M. Jesus García-Villanueva¹⁴, Jordi Monfort¹⁵, Norberto Ortego-Centeno¹⁶, Ainhoa Unzurrunzaga¹⁷, Begoña Marí-Alfonso¹⁸, Julio Sánchez-Martín¹⁹, Eugenio de Miguel²⁰, Cesar Magro²¹, Enrique Raya²², Niko Braun²³, Joerg Latus²⁴, Øyvind Molberg²⁵, Benedicte A. Lie²⁶, Frank Moosig²⁷, Torsten Witte²⁸, Ann W. Morgan², Miguel A. González-Gay²⁹ and Javier Martin³, ¹Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas, Armilla (Granada), Spain, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain, ⁴Instituto de Parasitología y Biomedicina 'López-Neyra' (IPBLN-CSIC), Granada, Spain, ⁵Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain, ⁶Rheumatology, Division of Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ⁷Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁸Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁹Rheumatology, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, ¹⁰Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ¹¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹²Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ¹³Thrombosis and Vasculitis Unit-Internal Medicine, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain, ¹⁴Rheumatology, Hospital Ramón y Cajal, Madrid, Spain, ¹⁵Reumatologia, Hospital del Mar, Barcelona, Spain, ¹⁶Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹⁷Internal Medicine, Hospital de Galdakano, Vizcaya, Spain, ¹⁸Internal Medicine, Corporació Sanitaria Parc Taulí, Instituto Universitario Parc Taulí, UAB, Sabadell, Spain, ¹⁹Rheumatology,, Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰Rheumatology, University Hospital La Paz - IdiPaz, Madrid, Spain, ²¹Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, ²²Rheumatology, University Hospital San Cecilio, Granada, Spain, ²³Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany, ²⁴Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany, ²⁵Oslo University Hospital, Oslo, Norway, ²⁶Department of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway, ²⁷Department of Clinical Immunology and Rheumatology, University of Luebeck, Bad Bramstedt, Germany, ²⁸Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ²⁹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: The PTPN22/CSK signaling represents one of the common susceptibility pathways in autoimmunity. Considering that the genetic basis of giant cell arteritis (GCA), an autoimmune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].